Delving into the Latest Updates on Parke, Davis & Co. LLC with Synapse

概览

疾病领域	数量

神经系统疾病	4
感染	3

排名前五的药物类型	数量

小分子化药	6

排名前五的靶点	数量

VDCCs(电压门控性钙通道复合体)	2
Bacterial Top II(细菌拓扑异构酶II)	1
Bacterial DNA gyrase x Bacterial Top II x Topoisomerase IV	1
SCNA(电压门控钠通道α亚基家族)	1
MAO(单胺氧化酶家族)	1

关联

19

项与 Parke, Davis & Co. LLC 相关的药物

Amodiaquine Hydrochloride

盐酸阿莫地喹

靶点-

作用机制-

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2005-10-28

Fosphenytoin Sodium

磷苯妥英钠

靶点

SCNA

作用机制

SCNA阻滞剂

在研机构

Hikma Pharmaceuticals USA, Inc. [+4]

原研机构

Pfizer Inc.

在研适应症

癫痫 [+4]

非在研适应症

急性疼痛 [+3]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1996-08-05

Colistin Sulfate

硫酸多粘菌素E

靶点-

作用机制-

在研机构

扬州制药有限公司

原研机构

Pfizer Inc.

在研适应症

志贺氏菌感染 [+1]

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期1984-01-01

100 项与 Parke, Davis & Co. LLC 相关的临床结果

登录后查看更多信息

0 项与 Parke, Davis & Co. LLC 相关的专利（医药）

登录后查看更多信息

3,424

项与 Parke, Davis & Co. LLC 相关的文献（医药）

2011-04-12·Journal of Pharmacy and Pharmacology3区 · 医学

The topical anti-inflammatory effects of a topical preparation of meclofenamic acid on carrageenan-induced footpad swelling in mice

3区 · 医学

Article

作者: Moniot, Susan ; Gluckman, Melvyn I ; Gilbertsen, Richard B ; Schrier, Denis J

AbstractA topical preparation of meclofenamic acid (Meclomen) was tested for anti-inflammatory activity in a murine model of carrageenan footpad oedema. The preparation significantly inhibited swelling when applied to the carrageenan-injected paw. Maximum inhibition was observed 4–5 h after carrageenan injection. The topical effects could not be attributed to systemic absorption because the preparation was more inhibitory when applied topically to the carrageenan-injected paw than to a distant site or orally.

2011-04-12·Journal of Pharmacy and Pharmacology3区 · 医学

Genotropic agents: Steroid basic ethers

3区 · 医学

Article

作者: Evans, D E ; Evans, D D ; Palmer, P J ; Weyell, D J ; Lewis, G S

AbstractThe synthesis and biological activity of a series of basic ethers of the steroid oestrogens is described. The compounds have genotropic (Black, 1961) activity coupled with low oestrogenicity.

2007-01-01·Principles of Clinical Pharmacology

Population Pharmacokinetics

作者: Raymond Miller

Publisher Summary This chapter discusses various aspects of population pharmacokinetics (PK). PK studies in patients have led to the appreciation of the large degree of variability in PK parameter estimates that exists across patients. Population PK parameters quantify population mean kinetics, between-subject variability (intersubject variability), and residual variability. Residual variability includes within-subject variability, model misspecification, and measurement error. The structural kinetic models used when performing a population analysis do not differ at all from those used for analysis of data from an individual patient. The chapter describes nonlinear mixed-effects method using the conventions of the NONMEM software. Each individual PK parameter can be expressed as a population mean and a deviation—typical for an individual. The deviation is the difference between the population mean and the individual parameter and is assumed to be a random variable with an expected mean of zero and variance. The nonlinear mixed-effect analysis avoids many of these deficiencies and provides a flexible means of estimating population PK parameters.

100 项与 Parke, Davis & Co. LLC 相关的药物交易

登录后查看更多信息

100 项与 Parke, Davis & Co. LLC 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年12月23日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

2

4

批准上市

其他

13

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

硫酸苯乙肼 ( MAO )	意识障碍更多	批准上市
乙琥胺 ( VDCCs )	失神发作更多	批准上市
磷苯妥英钠 ( SCNA )	癫痫持续状态更多	批准上市
甲琥胺 ( VDCCs )	癫痫发作更多	批准上市
克林沙星 ( Bacterial DNA gyrase x Bacterial Top II x Topoisomerase IV )	细菌感染更多	临床前